ArticleDiscover oncology2026
Identification of mitochondrial oxidative stress-related genes for estimating prognosis, immune infiltration landscape and drug candidates in pancreatic adenocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPancreatic adenocarcinoma (PAAD) represents a highly lethal form of cancer. Mitochondrial stress responses play a critical role in cancer development and therapeutic responses.
methodsTranscriptomic and clinical survival data for PAAD and normal pancreatic tissues were sourced from TCGA, GEO, and GTEx databases. Random survival forest and Cox regression analyses were used to identify MOS prognostic genes and construct a prognostic risk model. Subsequently, receiver operating characteristic (ROC) curve analysis, calibration curve analysis, and decision curve analysis were performed to evaluate the model’s performance in both the training and validation sets. Finally, enrichment analysis, protein-protein interaction network construction, unsupervised cluster analysis, tumor immune microenvironment assessment, and chemotherapeutic drug sensitivity analyses were conducted. Finally, we also performed RT-qPCR for validation.
resultsFive MOS-related genes were identified to construct the risk signature: ABCG1, CENPT, GMNN, NOG, and TOP2A. The predictive performance of the risk signature was validated in both the training set (TCGA) and the test sets (GSE62452 and GSE78229), with areas under the ROC curve for 3-year survival being 0.77, 0.74, and 0.75, respectively. Mechanistically, functional enrichment analysis revealed that pathways associated with cancer cell proliferation and mitochondrial stress responses were upregulated in the high-risk population. Furthermore, specific small molecules may hold therapeutic potential for treating PAAD patients. RT-qPCR results validated the changes in relative RNA expression levels.
conclusionThis study demonstrates that mitochondrial oxidative stress is correlated with the prognosis of PAAD and may serve as a novel biomarker and therapeutic target for clinical diagnostics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.